Viera Illíková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Viera Illíková has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jaroslav Tomko
Department of Arrhythmias and Cardiac Pacing Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases in Bratislava Bratislava Slovakia
2 shared publications - Marko Bjeloševič
Department of Paediatric Cardiology, Faculty of Medicine Comenius University in Bratislava Bratislava Slovakia
2 shared publications - Michal Chalupka
Department of Arrhythmias and Cardiac Pacing Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases in Bratislava Bratislava Slovakia
2 shared publications - Peter Olejnik
Department of Pediatric, Comenius University , Bratislava
2 shared publications - Robert Hatala
Department of Cardiac Electrophysiology, National Institute of Cardiovascular Diseases , Pod Krásnou hôrkou 1, Bratislava SK-83348
1 shared publication
Latest Publications
- Open Access
- 8 March 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (2)
Implantable Cardioverter‐Defibrillators in Children: A 14‐Year Population‐Based Study
Aims: Implantable cardioverter‐defibrillator (ICD) therapy in children, particularly for primary prevention, remains under investigation, with limited data from less affluent European countries. With increasing use of fully subcutaneous (S‐ICD) and extravascular (EV‐ICD) systems, we analyzed epidemiology, indications, complications, and outcomes in pediatric ICD recipients at our tertiary center. Methods: This retrospective, population‐based, nationwide, single‐center study consecutively analyzed medical records from 2012 to 2025. Patients aged 0–18 years who underwent ICD implantation were included. Kaplan–Meier analyses were performed for shock‐free and mortality endpoints. Results: Forty‐nine patients were included, corresponding to an estimated national incidence of approximately one ICD implantation per 22 000 live births. ICDs were predominantly implanted for secondary prevention (80%). Long QT syndrome (32%) and hypertrophic cardiomyopathy (22%) were the most frequent diagnoses. During 207 patient‐years of follow‐up (median follow‐up 4 years), appropriate ICD shocks occurred in 27% of patients exclusively in the secondary prevention group. No appropriate therapies occurred in the primary prevention group despite higher overall mortality. Inappropriate shocks occurred in 22% of patients. Device‐related major complications affected 17% of implanted systems. Median transvenous ICD battery longevity was 6.5 years. Overall mortality was 6%, all related to underlying structural heart disease, with no ICD‐related deaths. S‐ICDs demonstrated a favorable acute and mid‐term safety profile in patients without pacing requirements. Conclusions: Pediatric ICD therapy is limited by substantial device‐related morbidity and imperfect risk stratification for primary prevention. The emerging S‐ICD and EV‐ICD systems represent promising, less invasive alternatives for selected pediatric patients.
- 8 March 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (2)
Open AccessImplantable Cardioverter‐Defibrillators in Children: A 14‐Year Population‐Based Study
Aims: Implantable cardioverter‐defibrillator (ICD) therapy in children, particularly for primary prevention, remains under investigation, with limited data from less affluent European countries. With increasing use of fully subcutaneous (S‐ICD) and extravascular (EV‐ICD) systems, we analyzed epidemiology, indications, complications, and outcomes in pediatric ICD recipients at our tertiary center. Methods: This retrospective, population‐based, nationwide, single‐center study consecutively analyzed medical records from 2012 to 2025. Patients aged 0–18 years who underwent ICD implantation were included. Kaplan–Meier analyses were performed for shock‐free and mortality endpoints. Results: Forty‐nine patients were included, corresponding to an estimated national incidence of approximately one ICD implantation per 22 000 live births. ICDs were predominantly implanted for secondary prevention (80%). Long QT syndrome (32%) and hypertrophic cardiomyopathy (22%) were the most frequent diagnoses. During 207 patient‐years of follow‐up (median follow‐up 4 years), appropriate ICD shocks occurred in 27% of patients exclusively in the secondary prevention group. No appropriate therapies occurred in the primary prevention group despite higher overall mortality. Inappropriate shocks occurred in 22% of patients. Device‐related major complications affected 17% of implanted systems. Median transvenous ICD battery longevity was 6.5 years. Overall mortality was 6%, all related to underlying structural heart disease, with no ICD‐related deaths. S‐ICDs demonstrated a favorable acute and mid‐term safety profile in patients without pacing requirements. Conclusions: Pediatric ICD therapy is limited by substantial device‐related morbidity and imperfect risk stratification for primary prevention. The emerging S‐ICD and EV‐ICD systems represent promising, less invasive alternatives for selected pediatric patients.
- 27 May 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (7) , 680-686
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10‐year population‐based study
Background We aimed to evaluate the incidence, type and management of supraventricular tachyarrhythmias (SVT) during the first year of life in a retrospective, population‐based, single‐center study during a 10‐year period. Methods The analyzed patient cohort is based on data from the only specialized center managing all cases of neonatal and infant SVTs between 2009 and 2018 in the Slovak Republic (5.5 million population). A total of 116 consecutive patients < 366 days old were included in the study. Results Calculated SVT incidence was 1:4500 in the first year of life. AV reentry tachycardia was the leading arrhythmia (49%). SVT in this specific population was frequently a transient problem with spontaneous resolution in 87% of patients during a median 3‐year follow‐up. Congenital heart disease was common (16%). Intrauterine treatment by drugs administered to mother was safe and effective in preventing unnecessary cesarean deliveries. In arrhythmia termination amiodarone and propafenone were equally safe and effective, with possible more favorable pharmacodynamics of the former. For prophylactic treatment sotalol and propafenone were equally safe and effective and became the preferred basis of long‐term drug therapy in our center. However, this therapy requires intensive monitoring during its initiation. Conclusion The prognosis of SVT in the first year of life is good: with optimized pharmacological treatment the need for early catheter ablation and mortality rate are low (< 1%) and there is a high rate of spontaneous arrhythmia resolution. Heart failure is a possible predictor of arrhythmia persistence with need for ablation in later life. This article is protected by copyright. All rights reserved
- 27 May 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (7) , 680-686
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10‐year population‐based study
Background We aimed to evaluate the incidence, type and management of supraventricular tachyarrhythmias (SVT) during the first year of life in a retrospective, population‐based, single‐center study during a 10‐year period. Methods The analyzed patient cohort is based on data from the only specialized center managing all cases of neonatal and infant SVTs between 2009 and 2018 in the Slovak Republic (5.5 million population). A total of 116 consecutive patients < 366 days old were included in the study. Results Calculated SVT incidence was 1:4500 in the first year of life. AV reentry tachycardia was the leading arrhythmia (49%). SVT in this specific population was frequently a transient problem with spontaneous resolution in 87% of patients during a median 3‐year follow‐up. Congenital heart disease was common (16%). Intrauterine treatment by drugs administered to mother was safe and effective in preventing unnecessary cesarean deliveries. In arrhythmia termination amiodarone and propafenone were equally safe and effective, with possible more favorable pharmacodynamics of the former. For prophylactic treatment sotalol and propafenone were equally safe and effective and became the preferred basis of long‐term drug therapy in our center. However, this therapy requires intensive monitoring during its initiation. Conclusion The prognosis of SVT in the first year of life is good: with optimized pharmacological treatment the need for early catheter ablation and mortality rate are low (< 1%) and there is a high rate of spontaneous arrhythmia resolution. Heart failure is a possible predictor of arrhythmia persistence with need for ablation in later life. This article is protected by copyright. All rights reserved